The study of the analgesic and anti-edematous activity of purified naphthalan oil on the model of psoriasis
DOI:
https://doi.org/10.24959/nphj.25.176Keywords:
purified naphthalan oil; salicylic acid; psoriasis; carrageenan; analgesic activity; anti-edematous activityAbstract
Aim. To study the analgesic and anti-edematous activity of test samples of soft dosage forms containing purified naphthalan oil (PNO) on the model of psoriasis-like skin lesions and with additional inflammation induced by carrageenan.
Materials and methods. Psoriasis-like skin lesions were modeled by applying imiquimod to mice on a shaved area of the back skin. Additional inflammation was induced by injecting carrageenan under the plantar aponeurosis of the hind limb. The analgesic and anti-edematous effects of test samples of soft dosage forms containing PNO were studied, namely, an ointment with 10 % purified naphthalan oil and 3 % salicylic acid (PNO-SA), a cream with 10 % purified naphthalan oil and 0.064 % betamethasone dipropionate (PNO-BD), a cream with 10 % purified naphthalan oil and 10 % urea (PNO-U), and a cream with 10 % purified naphthalan oil, 0.064 % betamethasone dipropionate, and 10 % urea (PNO-BD-U). The analgesic effect of the test samples was assessed using the “tail flick” test to determine the pain threshold. The anti-edematous effect was evaluated by measuring the paw volume (standard units) using the plethysmometric method with the subsequent calculation of anti-edematous activity (AEA).
Results. It was found that in mice with psoriasis-like skin lesions, test samples containing PNO did not exhibit algogenic effects or increase the pain sensitivity. The PNO-SA ointment demonstrated a statistically significant higher pain threshold or a tendency toward a higher pain threshold on Day 14 of the treatment. In conditions of additional pain induction by carrageenan, all groups receiving PNO test samples showed an increased pain threshold 4 hours after phlogogen administration. The PNO-SA, PNO-U, and PNO-BD-U test samples also exhibited higher pain threshold values compared to the pathology control group. These findings suggest the analgesic effect of soft dosage forms containing PNO. It was found that the highest anti-edematous effect was observed in the PNO-SA group 2 hours after carrageenan administration (AEA 78.6 %) and in the PNO-U group 4 hours after administration (AEA 91.7 %). At the same time, in the PNO-SA group, unlike the other groups, there was no statistically significant increase in the paw volume during the experiment.
Conclusions. Among the test samples studied, PNO-SA is of the greatest interest taking into account the analgesic and anti-edematous activity. It is advisable to conduct further studies to assess the effectiveness and safety of this dosage form in models of psoriasis-like skin lesions in vitro and in vivo in order to develop a medicinal product for psoriasis treatment.
References
Bu, J., Ding, R., Zhou, L., Chen X., & Shen E. (2022). Epidemiology of psoriasis and comorbid diseases: A narrative review. Front. Immuno, 13, 880201. https://doi.org/10.3389/fimmu.2022.880201
Ramic, L., & Sator P. (2023). Topical treatment of psoriasis vulgaris. J. Dtsch. Dermatol. Ges, 21(6), 631-642. https://doi.org/10.1111/ddg.15042.
Reid, C., & Griffiths C. E. M. (2020). Psoriasis and treatment: Past, present and future aspects. Acta Derm. Venereol, 100(3), adv00032. https://doi.org/10.2340/00015555-3386.
Damiani, G., Bragazzi, N. L., Aksut, C. K., Wu, D., Alicandro, G., McGonagle, D., Guo, C., Dellavalle, R., Grada, A., Wong, P., La Vecchia, C., Tam, L.-S., Cooper, K. D., & Naghavi, M. (2021). The global, regional, and national burden of psoriasis: Results and insights from the global burden of disease 2019 study. Front. Med. (Lausanne), 8, 743180. https://doi.org/10.3389/fmed.2021.743180.
Adigozalova, V. A. (2023). Naftalan oil is a specific balneological factor of Azerbaijan. Azerbaijan J. Phys, 38(1), 48-56. https://doi.org/10.59883/ajp.52.
Zaychenko, G. V., Gorchakova, N. O., & Gorbach A. O. (2024). Teoretychne i eksperymentalne obgruntuvannia rozroblennia dermatolohichnykh likarskikh zasobiv na osnovi pryrodnykh spoluk naftalanskoii nafty. Phytotherapy. J, 3, 52-61. https://doi.org/10.32782/2522-9680-2024-3-52.
Schlager, J. G., Rosumeck, S., & Werner R. N. (2016). Topical treatments for psoriasis scalp. Cochrane Database Syst. Rev, 2(2), CD009687. https://doi.org/10.1002/14651858.CD009687.pub2.
Torsekar, R., & Gautam, M. M. (2017). Topical therapies in psoriasis. Indian Dermatol. Online J, 8(4), 235-245. https://doi.org/10.4103/2229-5178.209622.
Hawkes, J. E., Gudjonsson, J. E., & Ward N. L. (2017). The snowballing literature on imiquimod-induced skin inflammation in mice: A critical appraisal. J. Invest. Dermatol, 137(3), 546-549. https://doi.org/10.1016/j.jid.2016.10.024.
Mease, P. J. (2011). Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. (Hoboken), 63, Suppl. 11, S64-S85. https://doi.org/10.1002/acr.20577.
Doklinichni doslidzhennia likarskykh zasobiv: metod. rek. (2001). (O. V. Stefanova, Red.). Avitsena.
Bannon, A. W., & Malmberg, A. B. (2007). Models of nociception: Hot-plate, tail-flick, and formalin tests in rodents. Curr. Protoc. Neurosci, 8, Unit 8.9. https://doi.org/10.1002/0471142301.ns0809s41.
McCarson, K. E., & Fehrenbacher, J. C. (2021). Models of inflammation: Carrageenan- or Complete Freund’s Adjuvant (CFA)-induced edema and hypersensitivity in the rat. Curr. Protoc, 1(7), e202. https://doi.org/10.1002/cpz1.202.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
